Sogo Pharmaceutical Co., Ltd.

Sugo Pharmaceutical Company Limited

Manabu Katsumata

Tomoyasu Tashiro

Saburo Uchikuga

Saburoh Uchikuga

Tomoko Ohsumi

Yasuko Osawa

Yuji Narutomi

Keiko Kiuchi

The present invention relates to a process for producing amino/guanidinothiosulfonic acid, which comprises treating a styrenedivinylbenzene copolymer sulfonate of amino/guanidinoethyl disulfoxide into contact with an alkali, selectively eluting amino/guanidinosulfinic acid, then reacting this product in a non-aqueous solvent in the presence of a base, and passing the reaction product through a weakly acidic cation exchange resin column; in accordance with the present invention, hypotaurine, thiotaurine and the like having a high purity can industrially be produced.

Process and producing taurine analogues

Process for producing taurine analogues

Taurine analogues are used for scavenging active oxygen compounds and preventing and minimizing damage to the skin from ultraviolet rays. The taurine analogues have the following formula: ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are as defined in the specification.

Methods for scavenging active oxygen compounds and preventing damage

The present invention concerns an enzyme inhibitor containing the compound represented by the following formula (I) as an effective ingredient: ##STR1## where R represents hydrogen or substituted or not substituted alkyl group, alkenyl group, aryl group or aralkyl group, X represents OR' or NR'R'', in which R', R' and R'' represent respectively hydrogen or substituted or not substituted alkyl group, alkenyl group, aryl group or aralkyl group. The enzyme inhibitor according to the present invention can effectively inhibit aldose reductase, glyoxalase I and reverse transcriptase.

Pyrroloquinoline quinone compounds useful as an enzyme inhibitor

Growing community of inventors

Kanagawa-ken, Japan

Manabu Katsumata